Kristi Perry, PA-C Eli Luft, PA-C Key Takeaways 1
Start your journey to a healthier you today
Since obesity is a chronic illness that can lead to type 2 diabetes, cardiovascular disease, certain cancers, and sleep disorders, the FDA responded by approving the use of semaglutide in increased dosages for treating obesity and overweight individuals with certain weight-related diseases
These effects are mediated by: Improved endothelial function and nitric oxide bioavailability Reduced vascular inflammation and oxidative stress Stabilization of atherosclerotic plaque Enhanced cardiac metabolism and mitochondrial efficiency From a longevity standpoint, microdosing may maintain low-grade GLP-1 receptor activation within vascular tissue, supporting arterial flexibility, autonomic tone, and lipid regulation without the gastrointestinal intolerance often limiting high-dose use
Levothyroxine (T4) is the standard first-line treatment for hypothyroidism on the NHS
